Innovent Biologics Past Earnings Performance
Past criteria checks 0/6
Innovent Biologics has been growing earnings at an average annual rate of 27.1%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 36.3% per year.
Key information
27.1%
Earnings growth rate
57.3%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 36.3% |
| Return on equity | -8.2% |
| Net Margin | -16.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Innovent Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6,206 | -1,028 | 3,851 | 2,228 |
| 30 Sep 23 | 5,612 | -1,198 | 3,594 | 2,424 |
| 30 Jun 23 | 5,018 | -1,368 | 3,336 | 2,620 |
| 31 Mar 23 | 4,787 | -1,774 | 3,381 | 2,745 |
| 31 Dec 22 | 4,556 | -2,179 | 3,426 | 2,871 |
| 30 Sep 22 | 4,562 | -2,427 | 3,633 | 2,697 |
| 30 Jun 22 | 4,568 | -2,676 | 3,840 | 2,523 |
| 31 Mar 22 | 4,419 | -2,702 | 3,633 | 2,423 |
| 31 Dec 21 | 4,270 | -2,729 | 3,426 | 2,323 |
| 30 Sep 21 | 4,536 | -2,061 | 2,981 | 2,170 |
| 30 Jun 21 | 4,801 | -1,394 | 2,536 | 2,018 |
| 31 Mar 21 | 4,323 | -1,196 | 2,157 | 1,935 |
| 31 Dec 20 | 3,844 | -998 | 1,778 | 1,851 |
| 30 Sep 20 | 2,765 | -1,306 | 1,507 | 1,642 |
| 30 Jun 20 | 1,686 | -1,614 | 1,236 | 1,432 |
| 31 Mar 20 | 1,367 | -1,667 | 1,092 | 1,363 |
| 31 Dec 19 | 1,048 | -1,720 | 948 | 1,295 |
| 30 Sep 19 | 699 | -4,125 | 783 | 1,384 |
| 30 Jun 19 | 351 | -6,530 | 618 | 1,472 |
| 31 Mar 19 | 180 | -6,151 | 487 | 1,347 |
| 31 Dec 18 | 9 | -5,771 | 356 | 1,222 |
| 30 Sep 18 | 39 | -3,041 | 248 | 1,014 |
| 30 Jun 18 | 69 | -311 | 139 | 807 |
| 31 Mar 18 | 72 | -437 | 113 | 709 |
| 31 Dec 17 | 75 | -562 | 88 | 612 |
| 31 Dec 16 | 29 | -504 | 57 | 385 |
Quality Earnings: 1801 is currently unprofitable.
Growing Profit Margin: 1801 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1801 is unprofitable, but has reduced losses over the past 5 years at a rate of 27.1% per year.
Accelerating Growth: Unable to compare 1801's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1801 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 1801 has a negative Return on Equity (-8.21%), as it is currently unprofitable.